| Page 1824 | Kisaco Research
Review from Animal Health Asia 2018
 

Charlie Cannell

Digital Director
Inflexion Private Equity

Charlie is responsible for helping accelerate digital transformation within Inflexion’s portfolio companies and the appraisal of potential investment opportunities. Inflexion is an award-winning UK mid-market private equity firm investing between £10m and £150m in high growth, entrepreneurial businesses. Charlie works with Inflexion’s portfolio companies, which include MyPolicy, Scott Dunn and Virgin Experience Days, to drive growth and cutting-edge digital transformation. 

Read full bio

Charlie Cannell

Digital Director
Inflexion Private Equity

Charlie Cannell

Digital Director
Inflexion Private Equity

Charlie is responsible for helping accelerate digital transformation within Inflexion’s portfolio companies and the appraisal of potential investment opportunities. Inflexion is an award-winning UK mid-market private equity firm investing between £10m and £150m in high growth, entrepreneurial businesses. Charlie works with Inflexion’s portfolio companies, which include MyPolicy, Scott Dunn and Virgin Experience Days, to drive growth and cutting-edge digital transformation. 

 Prior to joining Inflexion in 2013, Charlie pioneered the introduction of digital products and services with BT, Abbott Mead Vickers BBDO, Digitas and Brunswick Group.

 

Julien Muller

CEO
Holidog

Julien Muller

CEO
Holidog

Julien Muller

CEO
Holidog
 

Mariot Chauvin

Head of Engineering
The Guardian

Mariot Chauvin

Head of Engineering
The Guardian

Mariot Chauvin

Head of Engineering
The Guardian
 

Russell Warman

Head of Infrastructure
Auto Trader UK

Russell Warman is Head of Infrastructure and Operations at Auto Trader, the UK's largest digital automotive marketplace

He leads the team charged with the capacity and performance of one the UK’s busiest websites - autotrader.co.uk, which sits at the heart of the UK's vehicle buying process. The team have a cloud native approach to enable our developers to make more frequent changes safely and are increasingly looking at public cloud services to help achieve that aim.

Read full bio

Russell Warman

Head of Infrastructure
Auto Trader UK

Russell Warman

Head of Infrastructure
Auto Trader UK

Russell Warman is Head of Infrastructure and Operations at Auto Trader, the UK's largest digital automotive marketplace

He leads the team charged with the capacity and performance of one the UK’s busiest websites - autotrader.co.uk, which sits at the heart of the UK's vehicle buying process. The team have a cloud native approach to enable our developers to make more frequent changes safely and are increasingly looking at public cloud services to help achieve that aim.

Best in Show Finalists 2020
 
European Protein Degradation Congress
22-23 May 2019
Basel, Switzerland
“Targeted protein degradation promises to be the greatest innovation in small molecule drug discovery in the new millennium.” - Manfred Koegl, Lab Head Oncology Research, Boehringer IngelheimWith capital investment coming in fast, industry is ready to commercialise the therapeutic potential of PROTACs and molecular glues to build safe, effective targeted protein degradation products. As Arvinas conducts the groundbreaking first PROTAC clinical trials this year, it could be only be a matter of time before PROTACs and molecular glues enter the market. The European Protein Degradation Congress will bring together leading industry players within big pharma and biotech along with expert academics in the ubiquitin space - providing an open forum and facilitate the sharing of in vitro and in vivo data, as well as build a deeper mechanistic understanding of the ubiquitin pathways and techniques to make the ‘undruggable’ druggable.Expect to hear strategies to overcome the structural biology, pharmacology and chemistry obstacles associated with the discovery and development of these bi-functional and single entity molecules.
Visit Site
 

Gwenn Hansen

Vice President of Drug Discovery Technologies
Nurix Therapeutics

Gwenn is Vice President of Drug Discovery Technologies at Nurix Therapeutics, a company focused on discovering and developing next-generation therapies that target protein homeostasis through modulation of the ubiquitin proteasome system. Since joining Nurix in January of 2016, Gwenn has focused on establishing the company’s DNA encoded library technology platform for small molecule discovery, and now leads teams of scientists in both early discovery as well as medicinal chemistry.

Read full bio

Gwenn Hansen

Vice President of Drug Discovery Technologies
Nurix Therapeutics

Gwenn Hansen

Vice President of Drug Discovery Technologies
Nurix Therapeutics

Gwenn is Vice President of Drug Discovery Technologies at Nurix Therapeutics, a company focused on discovering and developing next-generation therapies that target protein homeostasis through modulation of the ubiquitin proteasome system. Since joining Nurix in January of 2016, Gwenn has focused on establishing the company’s DNA encoded library technology platform for small molecule discovery, and now leads teams of scientists in both early discovery as well as medicinal chemistry. Prior to joining Nurix, Gwenn spent one year as an Associate Professor in the Center for Drug Discovery at Baylor College of Medicine and over 13 years in a variety of discovery-focused roles at Lexicon Pharmaceuticals, both located in Houston, Texas.  Gwenn received her PhD in Biomedical Sciences from Oak Ridge National Laboratory in 1998 and completed postdoctoral training at MD Anderson Cancer Center.